{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:36:18Z","timestamp":1793730978007,"version":"4.6.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02309-x","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:37:00Z","timestamp":1775122620000},"page":"779-795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral Gut-Restricted Targeted Therapy for IBD: A Pipeline Review"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5098-8729","authenticated-orcid":false,"given":"Joana","family":"Roseira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5158-2321","authenticated-orcid":false,"given":"Marianne","family":"Hup\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4374-3042","authenticated-orcid":false,"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"2","key":"2309_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41575-022-00738-z","volume":"20","author":"T Kobayashi","year":"2023","unstructured":"Kobayashi T, Hibi T. Improving ibd outcomes in the era of many treatment options. Nat Rev Gastroenterol Hepatol. 2023;20(2):79\u201380.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"2309_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41573-024-00953-0","volume":"23","author":"S Honap","year":"2024","unstructured":"Honap S, Jairath V, Danese S, Peyrin-Biroulet L. Navigating the complexities of drug development for inflammatory bowel disease. Nat Rev Drug Discov. 2024;23(7):546\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2309_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(1):69-81 e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2309_CR4","doi-asserted-by":"crossref","unstructured":"Ahuja D, Yeh KH, Patel SB, Lee HH, Goodwin SW, Solitano V, et al. Comparative safety of Janus kinase inhibitors vs tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Clin Gastroenterol hepatol. 2025.","DOI":"10.1016\/j.cgh.2025.06.041"},{"issue":"8","key":"2309_CR5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/2211-5463.13668","volume":"13","author":"CK Murphy","year":"2023","unstructured":"Murphy CK, Dixit B, Oleson FB, Dolle RE, Farquhar R, Mccormick BA. Development of ads051, an oral, gut-restricted, small molecule neutrophil modulator for the treatment of neutrophil-mediated inflammatory diseases. FEBS Open Bio. 2023;13(8):1434\u201346.","journal-title":"FEBS Open Bio"},{"issue":"5","key":"2309_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1021\/acschembio.2c00057","volume":"17","author":"K Griffett","year":"2022","unstructured":"Griffett K, Hayes M, Bedia-diaz G, Appourchaux K, Sanders R, Boeckman MP, et al. Antihyperlipidemic activity of gut-restricted LXR inverse agonists. ACS Chem Biol. 2022;17(5):1143\u201354.","journal-title":"ACS Chem Biol"},{"issue":"4","key":"2309_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/ibd\/izac119","volume":"29","author":"A Buisson","year":"2023","unstructured":"Buisson A, Serrero M, Orsat L, Nancey S, Riviere P, Altwegg R, et al. comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide accept2 study. Inflamm Bowel Dis. 2023;29(4):579\u201388.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2309_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2036.2007.03555.x","volume":"27","author":"R D\u2019inca","year":"2008","unstructured":"D\u2019inca R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC. risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27(2):166\u201372.","journal-title":"Aliment Pharmacol Ther"},{"key":"2309_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2025.1571982","volume":"5","author":"D Vllasaliu","year":"2025","unstructured":"Vllasaliu D. grand challenges in oral drug delivery. Front Drug Delivery. 2025;5:1571982.","journal-title":"Front Drug Delivery"},{"key":"2309_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejpb.2020.08.017","volume":"155","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Thanou M, Vllasaliu D. exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease. Eur J Pharm Biopharm. 2020;155:128\u201338.","journal-title":"Eur J Pharm Biopharm"},{"issue":"27","key":"2309_CR11","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383(27):2652\u201364.","journal-title":"N Engl J Med"},{"issue":"708","key":"2309_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7491","volume":"15","author":"DE Peters","year":"2023","unstructured":"Peters DE, Norris LD, Tenora L, Snajdr I, Ponti AK, Zhu X, et al. a gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis. Sci Transl Med. 2023;15(708):eabn7491.","journal-title":"Sci Transl Med"},{"issue":"11","key":"2309_CR13","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41564-024-01810-x","volume":"9","author":"UH Manjunatha","year":"2024","unstructured":"Manjunatha UH, Lakshminarayana SB, Jumani RS, Chao AT, Young JM, Gable JE, et al. cryptosporidium pi(4)k inhibitor edi048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis. Nat Microbiol. 2024;9(11):2817\u201335 (2024\/11\/01).","journal-title":"Nat Microbiol"},{"key":"2309_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106925","volume":"108","author":"S Feng","year":"2025","unstructured":"Feng S, Raimi-abraham BT, Vllasaliu D. Peg-plga nanoparticles transport across in vitro intestinal epithelial models and show potential for oral delivery of antibodies in inflammatory bowel disease. J Drug Delivery Sci Technol. 2025;108:106925 (2025\/06\/01\/).","journal-title":"J Drug Delivery Sci Technol."},{"issue":"4","key":"2309_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.48.4.571","volume":"48","author":"SG Nugent","year":"2001","unstructured":"Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal ph in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571\u20137.","journal-title":"Gut"},{"issue":"2","key":"2309_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.addr.2004.08.007","volume":"57","author":"U Klotz","year":"2005","unstructured":"Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev. 2005;57(2):267\u201379.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"2309_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437\u201344.","journal-title":"J Crohns Colitis"},{"issue":"18","key":"2309_CR18","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.3748\/wjg.v28.i18.1922","volume":"28","author":"F Yasmin","year":"2022","unstructured":"Yasmin F, Najeeb H, Shaikh S, Hasanain M, Naeem U, Moeed A, et al. Novel drug delivery systems for inflammatory bowel disease. World J Gastroenterol. 2022;28(18):1922\u201333.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2309_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40259-025-00739-9","volume":"39","author":"S Lazarevic","year":"2025","unstructured":"Lazarevic S, Danic M, Pavlovic N. Bidirectional interplay between ibd therapies and the gut microbiota: a pharmacomicrobiomic approach to personalized treatment. BioDrugs. 2025;39(6):877\u201397.","journal-title":"BioDrugs"},{"key":"2309_CR20","doi-asserted-by":"crossref","unstructured":"Rouco H, Diaz-rodriguez P, Gaspar DP, Goncalves LMD, Cuerva M, Remunan-lopez C, et al. Rifabutin-loaded nanostructured lipid carriers as a tool in oral anti-mycobacterial treatment of crohn\u2019s disease. Nanomaterials (basel). 2020;10(11).","DOI":"10.3390\/nano10112138"},{"key":"2309_CR21","unstructured":"European medicines agency. guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract. 2018; available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-equivalence-studies-demonstration-therapeutic-equivalence-locally-applied-locally-acting-products-gastrointestinal-tract-revision-1_en.pdf"},{"key":"2309_CR22","doi-asserted-by":"crossref","unstructured":"Gvozdeva Y, Staynova R. ph-dependent drug delivery systems for ulcerative colitis treatment. Pharmaceutics. 2025;17(2).","DOI":"10.3390\/pharmaceutics17020226"},{"issue":"11","key":"2309_CR23","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1097\/MIB.0b013e3182a11958","volume":"19","author":"KC Bhol","year":"2013","unstructured":"Bhol KC, Tracey DE, Lemos BR, Lyng GD, Erlich EC, Keane DM, et al. Avx-470: a novel oral anti-tnf antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(11):2273\u201381.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"2309_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/ecco-jcc\/jjw036","volume":"10","author":"MS Harris","year":"2016","unstructured":"Harris MS, Hartman D, Lemos BR, Erlich EC, Spence S, Kennedy S, et al. Avx-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohns Colitis. 2016;10(6):631\u201340.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2309_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/ecco-jcc\/jjw026","volume":"10","author":"DS Hartman","year":"2016","unstructured":"Hartman DS, Tracey DE, Lemos BR, Erlich EC, Burton RE, Keane DM, et al. Effects of avx-470, an oral, locally acting anti-tumour necrosis factor antibody, on tissue biomarkers in patients with active ulcerative colitis. J Crohns Colitis. 2016;10(6):641\u20139.","journal-title":"J Crohns Colitis"},{"key":"2309_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jim.2017.03.023","volume":"446","author":"E Almon","year":"2017","unstructured":"Almon E, Khoury T, Drori A, Gingis-Velitski S, Alon S, Chertkoff R, et al. An oral administration of a recombinant anti-tnf fusion protein is biologically active in the gut promoting regulatory t cells: results of a phase i clinical trial using a novel oral anti-tnf alpha-based therapy. J Immunol Methods. 2017;446:21\u20139.","journal-title":"J Immunol Methods"},{"issue":"2","key":"2309_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/MCG.0000000000001314","volume":"55","author":"E Almon","year":"2021","unstructured":"Almon E, Shaaltiel Y, Sbeit W, Fich A, Schwartz D, Waterman M, et al. Novel orally administered recombinant anti-tnf alpha fusion protein for the treatment of ulcerative colitis: results from a phase 2a clinical trial. J Clin Gastroenterol. 2021;55(2):134\u201340.","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl. 11","key":"2309_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000480232.55276.b3","volume":"22","author":"L Mattheakis","year":"2016","unstructured":"Mattheakis L, Bhandari A, Bai L, Zemede G, Tran V, Celino H, et al. ptg-100, an oral peptide antagonist of integrin alpha4beta7 that alters trafficking of gut homing t cells in preclinical animal models. Inflammatory Bowel Dis. 2016;22(Suppl. 11):s48.","journal-title":"Inflammatory Bowel Dis"},{"issue":"supplement 1","key":"2309_CR29","doi-asserted-by":"publisher","first-page":"s132","DOI":"10.1093\/ecco-jcc\/jjx002.239","volume":"11","author":"L Mattheakis","year":"2017","unstructured":"Mattheakis L, Fosser C, Saralaya R, Horsch K, Rao N, Bai L, et al. Model based predictions of the ptg-100 pharmacodynamic responses in ulcerative colitis patients. J Crohn\u2019s and Colitis. 2017;11(supplement 1):s132\u20133.","journal-title":"J Crohn's and Colitis."},{"issue":"6","key":"2309_CR30","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1053\/j.gastro.2021.08.045","volume":"161","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, et al. ptg-100, an oral alpha4beta7 antagonist peptide: preclinical development and phase 1 and 2a studies in ulcerative colitis. Gastroenterology. 2021;161(6):1853\u201364 (e10).","journal-title":"Gastroenterology"},{"issue":"12","key":"2309_CR31","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1093\/ecco-jcc\/jjac092","volume":"16","author":"S Bhat","year":"2022","unstructured":"Bhat S, Rieder F. Hypoxia-inducible factor 1-alpha stabilizers in the treatment of inflammatory bowel diseases: oxygen as a novel ibd therapy? J Crohns Colitis. 2022;16(12):1924\u201332.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2309_CR32","doi-asserted-by":"publisher","first-page":"g420","DOI":"10.1152\/ajpgi.00192.2020","volume":"320","author":"BJ Goggins","year":"2021","unstructured":"Goggins BJ, Minahan K, Sherwin S, Soh WS, Pryor J, Bruce J, et al. Pharmacological hif-1 stabilization promotes intestinal epithelial healing through regulation of alpha-integrin expression and function. Am J Physiol Gastrointest Liver Physiol. 2021;320(4):g420\u201338.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"2309_CR33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.072","volume":"158","author":"B Levesque","year":"2020","unstructured":"Levesque B, Meadows KT, Buch A, Flynn M, Peters K, Olson A, et al. gb004, a novel gut-targeted prolyl hydroxylase inhibitor for inflammatory bowel disease: first-in-human, mutliple-dose study in healthy subjects with gut biopsies. Gastroenterology. 2020;158(3):s15.","journal-title":"Gastroenterology"},{"issue":"4","key":"2309_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/apt.16753","volume":"55","author":"S Danese","year":"2022","unstructured":"Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, et al. Randomised clinical trial: a phase 1b study of gb004, an oral hif-1alpha stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther. 2022;55(4):401\u201311.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2309_CR35","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1097\/MCG.0b013e3181c29860","volume":"44","author":"W Stremmel","year":"2010","unstructured":"Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol. 2010;44(5):e101\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"2309_CR36","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/ajg.2014.104","volume":"109","author":"M Karner","year":"2014","unstructured":"Karner M, Kocjan A, Stein J, Schreiber S, Von Boyen G, Uebel P, et al. First multicenter study of modified release phosphatidylcholine \u201clt-02\u201d in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol. 2014;109(7):1041\u201351.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2309_CR37","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.cgh.2023.09.031","volume":"22","author":"A Dignass","year":"2024","unstructured":"Dignass A, Stremmel W, Horynski M, Poyda O, Armerding P, Fellermann K, et al. Modified-release phosphatidylcholine (lt-02) for ulcerative colitis: two double-blind, randomized, placebo-controlled trials. Clin Gastroenterol Hepatol. 2024;22(4):810\u201320.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2309_CR38","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","volume":"14","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, et al. development of gut-selective pan-janus kinase inhibitor td-1473 for ulcerative colitis: a translational medicine programme. J Crohns Colitis. 2020;14(9):1202\u201313.","journal-title":"J Crohns Colitis"},{"key":"2309_CR39","unstructured":"nct03758443. A phase 2b\/3 multi-center, randomized, double-blind, multi-dose, placebo-controlled, parallel-group set of studies to evaluate the efficacy and safety of induction and maintenance therapy with td-1473 in subjects with moderately-to-severely active ulcerative colitis. 2018; available from: https:\/\/clinicaltrials.gov\/study\/nct03758443"},{"key":"2309_CR40","unstructured":"Tirumalaraju D. Theravance\u2019s izencitinib fails in phase iib ulcerative colitis trial. 2021; available from: https:\/\/www.clinicaltrialsarena.com\/news\/theravance-izencitinib-ulcerative-colitis\/"},{"issue":"11","key":"2309_CR41","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/cpdd.946","volume":"10","author":"NB Modi","year":"2021","unstructured":"Modi NB, Cheng X, Mattheakis L, Hwang CC, Nawabi R, Liu D, et al. Single- and multiple-dose pharmacokinetics and pharmacodynamics of pn-943, a gastrointestinal-restricted oral peptide antagonist of alpha4beta7, in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10(11):1263\u201378.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"2309_CR42","first-page":"70","volume":"10","author":"S Plevy","year":"2022","unstructured":"Plevy S, Sands BE, Panes J, D\u2019haens GR, Jairath V, Feagan B, et al. A phase 2 randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted a4b7 integrin peptide antagonist pn-943 in patients with moderate to severe ulcerative colitis: results from the ideal study. United Euro Gastroenterol J. 2022;10:70\u20131.","journal-title":"United Euro Gastroenterol J."},{"key":"2309_CR43","unstructured":"United States securities and exchange commission. protagonist therapeutics, inc. 2023 form 10-k annual report. 2023; Available from: https:\/\/www.sec.gov\/ix?doc=\/archives\/edgar\/data\/1377121\/000155837024001850\/ptgx-20231231x10k.htm"},{"issue":"12","key":"2309_CR44","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","volume":"372","author":"G Monteleone","year":"2015","unstructured":"Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, et al. Mongersen, an oral smad7 antisense oligonucleotide, and crohn\u2019s disease. N Engl J Med. 2015;372(12):1104\u201313.","journal-title":"N Engl J Med"},{"issue":"5","key":"2309_CR45","doi-asserted-by":"publisher","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","volume":"115","author":"BE Sands","year":"2020","unstructured":"Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frederic Colombel J, et al. Mongersen (ged-0301) for active crohn\u2019s disease: results of a phase 3 study. Am J Gastroenterol. 2020;115(5):738\u201345.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2309_CR46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40259-021-00482-x","volume":"35","author":"I Marafini","year":"2021","unstructured":"Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, et al. A pharmacological batch of mongersen that downregulates smad7 is effective as induction therapy in active crohn\u2019s disease: a phase ii, open-label study. BioDrugs. 2021;35(3):325\u201336.","journal-title":"BioDrugs"},{"key":"2309_CR47","doi-asserted-by":"crossref","unstructured":"Monteleone G, Stolfi C. Smad7 antisense oligonucleotide in Crohn\u2019s disease: a re-evaluation and explanation for the discordant results of clinical trials. Pharmaceutics. 2022;15(1).","DOI":"10.3390\/pharmaceutics15010095"},{"issue":"5","key":"2309_CR48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40291-022-00606-1","volume":"26","author":"G Monteleone","year":"2022","unstructured":"Monteleone G, Stolfi C, Marafini I, Atreya R, Neurath MF. Smad7 antisense oligonucleotide-based therapy in crohn\u2019s disease: is it time to re-evaluate? Mol Diagn Ther. 2022;26(5):477\u201381.","journal-title":"Mol Diagn Ther"},{"key":"2309_CR49","doi-asserted-by":"crossref","unstructured":"Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Clare S, et al. Preclinical development of a novel, orally-administered anti-tumour necrosis factor domain antibody for the treatment of inflammatory bowel disease. Sci Rep. 2018;8(1):4941.","DOI":"10.1038\/s41598-018-23277-7"},{"key":"2309_CR50","unstructured":"nct02976129. phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with v565 in subjects with active crohn\u2019s disease. 2016; Aavailable from: https:\/\/clinicaltrials.gov\/study\/nct02976129"},{"key":"2309_CR51","unstructured":"nct04516382. an open-label crossover study evaluating the pharmacokinetics and pharmacodynamics of different ptg-300 regimens in healthy volunteers. 2020; Available from: https:\/\/clinicaltrials.gov\/study\/nct04516382"},{"key":"2309_CR52","unstructured":"United States securities and exchange commission. Protagonist Therapeutics, Inc. 2023 form 10-k annual report. 2023. 2023; Available from: https:\/\/www.sec.gov\/ix?doc=\/archives\/edgar\/data\/1377121\/000155837024001850\/ptgx-20231231x10k.htm"},{"key":"2309_CR53","unstructured":"nct04102111. A phase 2, multicenter, randomized, double-blind, placebo-controlled, platform study evaluating the efficacy and safety of interventions in participants with moderately to severely active Crohn\u2019s disease. 2019; Available from: https:\/\/clinicaltrials.gov\/study\/nct04102111."},{"key":"2309_CR54","unstructured":"United States securities and exchange commission. Protagonist Therapeutics, Inc. 2021 form 10-k annual report. 2021; Available from: https:\/\/www.sec.gov\/ix?doc=\/archives\/edgar\/data\/1377121\/000155837022002385\/ptgx-20211231x10k.htm"},{"issue":"supplement_1","key":"2309_CR55","doi-asserted-by":"publisher","first-page":"i62","DOI":"10.1093\/ecco-jcc\/jjae190.0031","volume":"19","author":"V Jairath","year":"2025","unstructured":"Jairath V, Danese S, D\u2019haens G, Feagan B, Peyrin-Biroulet L, Sands BE, et al. op31 phase 1b study of sor102, a novel, orally delivered bispecific anti-tnf\/anti-il-23 domain antibody in patients with mild to severe ulcerative colitis. J Crohns Colitis. 2025;19(supplement_1):i62\u20133.","journal-title":"J Crohns Colitis"},{"issue":"s8","key":"2309_CR56","volume":"13","author":"V Jairath","year":"2025","unstructured":"Jairath V, Roberts K, Terry A, Danese S, D\u2019haens G, Feagan B, et al. oral administration of sor102 delivers anti-tnf\/il-23 activity directly to colonic tissue and drives clinical and pharmacodynamic responses in ulcerative colitis patients. United Eur Gastroenterol J. 2025;13(s8):s674.","journal-title":"United Eur Gastroenterol J."},{"issue":"1","key":"2309_CR57","first-page":"19422","volume":"11","author":"KJ Roberts","year":"2021","unstructured":"Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, et al. Preclinical development of a bispecific tnf\u03b1\/il-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Reports. 2021;11(1):19422 (2021\/09\/30).","journal-title":"Sci Reports."},{"issue":"supplement_1","key":"2309_CR58","doi-asserted-by":"publisher","first-page":"i1111","DOI":"10.1093\/ecco-jcc\/jjad212.0702","volume":"18","author":"M Barreiro-De Acosta","year":"2024","unstructured":"Barreiro-De Acosta M, Skybalo S, Rodr\u00edguez C, Garc\u00eda-L\u00f3pez S, Mart\u00edn-Arranz M, Torrealba L, et al. p572 evaluation of safety, pharmacokinetics and efficacy of oral treatment with ost-122 in patients with moderate to severe ulcerative colitis: a phase ib\/iia, randomized, double blind, placebo controlled clinical trial. J Crohns Colitis. 2024;18(supplement_1):i1111\u20132.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2309_CR59","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.14309\/ajg.0000000000003269","volume":"120","author":"JR Allegretti","year":"2024","unstructured":"Allegretti JR, Cheifetz AS, Dulai PS, Stevens AC, Chapas-Reed J, Chesnel L, et al. Safety, pharmacokinetics, and clinical efficacy of ads051, a neutrophil modulator, in ulcerative colitis: results of a randomized phase 1b trial. Am J Gastroenterol. 2024;120(7):1624\u201335.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"2309_CR60","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.4049\/jimmunol.1900364","volume":"203","author":"A Leber","year":"2019","unstructured":"Leber A, Hontecillas R, Zoccoli-Rodriguez V, Bienert C, Chauhan J, Bassaganya-Riera J. Activation of nlrx1 by nx-13 alleviates inflammatory bowel disease through immunometabolic mechanisms in cd4(+) t cells. J Immunol. 2019;203(12):3407\u201315.","journal-title":"J Immunol"},{"issue":"5","key":"2309_CR61","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/ecco-jcc\/jjad192","volume":"18","author":"B Verstockt","year":"2024","unstructured":"Verstockt B, Vermeire S, Peyrin-Biroulet L, Mosig R, Feagan BG, Colombel JF, et al. the safety, tolerability, pharmacokinetics, and clinical efficacy of the nlrx1 agonist nx-13 in active ulcerative colitis: results of a phase 1b study. J Crohns Colitis. 2024;18(5):762\u201372.","journal-title":"J Crohns Colitis"},{"issue":"22","key":"2309_CR62","doi-asserted-by":"publisher","first-page":"10113","DOI":"10.1021\/acs.jmedchem.6b00412","volume":"59","author":"A Carbo","year":"2016","unstructured":"Carbo A, Gandour RD, Hontecillas R, Philipson N, Uren A, Bassaganya-Riera J. An n, n-bis(benzimidazolylpicolinoyl)piperazine (bt-11): a novel lanthionine synthetase c-like 2-based therapeutic for inflammatory bowel disease. J Med Chem. 2016;59(22):10113\u20131026.","journal-title":"J Med Chem"},{"issue":"4","key":"2309_CR63","first-page":"643","volume":"26","author":"A Leber","year":"2020","unstructured":"Leber A, Hontecillas R, Zoccoli-Rodriguez V, Colombel J-F, Chauhan J, Ehrich M, et al. The safety, tolerability, and pharmacokinetics profile of bt-11, an oral, gut-restricted lanthionine synthetase c-like 2 agonist investigational new drug for inflammatory bowel disease: a randomized, double-blind, placebo-controlled phase i clinical trial. Inflamm Bowel Dis. 2020;26(4):643\u201352.","journal-title":"Inflamm Bowel Dis"},{"issue":"1 supplement","key":"2309_CR64","doi-asserted-by":"publisher","first-page":"s-916","DOI":"10.1016\/S0016-5085(25)03039-2","volume":"169","author":"A Leber","year":"2025","unstructured":"Leber A, Hontecillas R, Tubau-Juni N, Bassaganya-Riera J. Omilancor reverses colonic treg depletion and mitochondrial metabolism downregulation in severe ulcerative colitis patients. Gastroenterology. 2025;169(1 supplement):s-916.","journal-title":"Gastroenterology"},{"key":"2309_CR65","doi-asserted-by":"crossref","unstructured":"Yadav V, House A, Matiz S, Mccoubrey LE, Bettano KA, Bhave L, et al. Ileocolonic-targeted jak inhibitor: a safer and more effective treatment for inflammatory bowel disease. Pharmaceutics. 2022;14(11).","DOI":"10.3390\/pharmaceutics14112385"},{"issue":"16","key":"2309_CR66","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1021\/jm020033k","volume":"45","author":"NJ Dubree","year":"2002","unstructured":"Dubree NJ, Artis DR, Castanedo G, Marsters J, Sutherlin D, Caris L, et al. Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents. J Med Chem. 2002;45(16):3451\u20137.","journal-title":"J Med Chem"},{"issue":"10","key":"2309_CR67","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ibd.21266","volume":"16","author":"C Wang","year":"2010","unstructured":"Wang C, Hanly EK, Wheeler LW, Kaur M, Mcdonald KG, Newberry RD. Effect of alpha4beta7 blockade on intestinal lymphocyte subsets and lymphoid tissue development. Inflamm Bowel Dis. 2010;16(10):1751\u201362.","journal-title":"Inflamm Bowel Dis"},{"issue":"94","key":"2309_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7549","volume":"9","author":"P Canales-Herrerias","year":"2024","unstructured":"Canales-Herrerias P, Uzzan M, Seki A, Czepielewski RS, Verstockt B, Livanos AE, et al. gut-associated lymphoid tissue attrition associates with response to anti-\u03b14\u03b27 therapy in ulcerative colitis. Sci Immunol. 2024;9(94):eadg7549.","journal-title":"Sci Immunol."},{"key":"2309_CR69","doi-asserted-by":"crossref","unstructured":"Sands BE, Schreiber S, Danese S, Kierkus J, Abhyankar B, Choi MY, et al. A phase 2 study of morf-057, an oral alpha4beta7 integrin inhibitor in moderately to severely active ulcerative colitis. Clin Gastroenterol Hepatol. 2025.","DOI":"10.1016\/j.cgh.2025.07.030"},{"issue":"s8","key":"2309_CR70","first-page":"174","volume":"13","author":"B Sands","year":"2025","unstructured":"Sands B, Feagan B, Schreiber S, Abhyankar B, Choi M, Wu Y, et al. Efficacy and safety of morf-057 therapy in adults with moderately to severely active ulcerative colitis: phase 2b emerald-2 study results through week 12. United Eur Gastroenterol J. 2025;13(s8):174.","journal-title":"United Eur Gastroenterol J."},{"key":"2309_CR71","first-page":"117","volume":"113","author":"J Zhou","year":"2024","unstructured":"Zhou J, Maramreddy N, Mcfarlane J, Zhou Y, Hong F, Othman AA. Pharmacokinetics, safety & tolerability of gs-1427, a pro-drug of a potent & selective small-molecule alpha4beta7 integrin inhibitor, in healthy volunteers. Clin Pharmacol Drug Development. 2024;113:117\u20138.","journal-title":"Clin Pharmacol Drug Development"},{"issue":"7","key":"2309_CR72","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","volume":"149","author":"N Yoshimura","year":"2015","unstructured":"Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, et al. Safety and efficacy of ajm300, an oral antagonist of \u03b14 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149(7):1775\u201383 (e2).","journal-title":"Gastroenterology"},{"issue":"7","key":"2309_CR73","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S2468-1253(22)00022-X","volume":"7","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, et al. ajm300 (carotegrast methyl), an oral antagonist of alpha4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(7):648\u201357.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"9","key":"2309_CR74","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40265-022-01732-0","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S. Carotegrast methyl: first approval. Drugs. 2022;82(9):1011\u20136 (2022\/06\/01).","journal-title":"Drugs"},{"issue":"9","key":"2309_CR75","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s13555-025-01454-7","volume":"15","author":"B Knight","year":"2025","unstructured":"Knight B, Tammara B, Modi NB, Dallas S, Mardirosian S, Wang J, et al. Translational pharmacokinetics of icotrokinra, a targeted oral peptide that selectively blocks interleukin-23 receptor and inhibits signaling. Dermatol Ther. 2025;15(9):2495\u2013520 (2025\/09\/01).","journal-title":"Dermatol Ther"},{"issue":"s8","key":"2309_CR76","first-page":"172","volume":"13","author":"M Abreu","year":"2025","unstructured":"Abreu M, Siegmund B, Surace L, Erondu N, Chen M, Chachu K, et al. op206 icotrokinra, a targeted oral peptide that selectively blocks il-23 receptor activation, in moderately to severely active ulcerative colitis: week 12 results from the phase 2b, randomized, double-blind, placebo-controlled, treat-through, dose-ranging anthem-uc trial. United Eur Gastroenterol J. 2025;13(s8):172\u20133.","journal-title":"United Eur Gastroenterol J"},{"issue":"18","key":"2309_CR77","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa2504187","volume":"393","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Soung J, Hebert AA, Pink AE, Pinter A, Moore AY, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393(18):1784\u201395.","journal-title":"N Engl J Med"},{"key":"2309_CR78","unstructured":"nct05785715. A randomized, double-blind, placebo-controlled, multiple dose, multicenter phase 2 induction study with long-term extension to evaluate the clinical activity and safety of oral nx-13 in participants w\/ moderate to severe ulcerative colitis. 2023; available from: https:\/\/clinicaltrials.gov\/study\/nct05785715"},{"issue":"1","key":"2309_CR79","volume":"18","author":"C Wang","year":"2023","unstructured":"Wang C, Xu M, Fan Q, Li C, Zhou X. therapeutic potential of exosome-based personalized delivery platform in chronic inflammatory diseases. Asian J Pharm Sci. 2023;18(1):100772.","journal-title":"Asian J Pharm Sci"},{"key":"2309_CR80","unstructured":"nct02768974. Open label study to assess safety, pk and explore efficacy of oprx-106 in patients with active mild to moderate ulcerative colitis. an open label, proof of concept study to assess the safety, pk and explore efficacy of oprx-106 in patients with active mild to moderate ulcerative colitis 2016; Available from: https:\/\/clinicaltrials.gov\/study\/nct02768974"},{"issue":"8","key":"2309_CR81","first-page":"70","volume":"10","author":"S Plevy","year":"2022","unstructured":"Plevy S, Sands BE, Panes J, D\u2019haens GR, Jairath V, Feagan B, et al. A phase 2 randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted a4b7 integrin peptide antagonist pn-943 in patients with moderate to severe ulcerative colitis: results from the ideal study. United Eur Gastroenterol J. 2022;10(8):70\u20131.","journal-title":"United Eur Gastroenterol J."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02309-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02309-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02309-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:03:50Z","timestamp":1778861030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02309-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2309"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02309-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JR received advisory board fees and speaker\u2019s fees from Abbvie and Janssen; MH received advisory board fees and speaker\u2019s fees from Takeda, Celltrion Healthcare, Amgen, Abbvie, Pfizer, and Johnson & Johnson; YY none to declare. FM served as speaker for Abbvie, Arena, Biogen, Bristol Myers Squibb, Falk, Ferring, Hospira, Janssen, Laborat\u00f3rios Vitoria, Pfizer, Lilly, Merck Sharp & Dohme, Sandoz, Takeda, UCB, and Vifor. VJ has received has received consulting\/advisory board fees from AbbVie, Alimentiv, Anaptyis Bio, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Endpoint Health, Enthera, Ensho, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Innomar, JAMP, Janssen, Merck, Metacrine, Mylan, MRM Health, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus Biosciences, Reistone Biopharma, Roche, Roivant, Sandoz, Second Genome, Sorriso, Spyre, Synedgen, Takeda,Teva, Ventyx, and Vividion and speaker\u2019s fees from, Abbvie, Ferring, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Janssen, Pfizer, Shire, Takeda, and Tillotts.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"JR, MH, YY, FM, and VJ contributed to the outline. The first draft of the manuscript was written by JR and MH. JR, MH, YY, FM, and VJ commented on previous versions of the manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}